Woman's World · Mar 2026
Feature article explaining the skin-pH rationale behind Soteri Skin's approach and describing clinical results and barrier-repair framing.
Company research
Public company, workplace, funding, and market signals
Updated Jul 29, 2026
Overview
Soteri Skin is a Harvard-developed, Y Combinator-backed direct-to-consumer skincare company focused on non-steroidal, pH-correcting eczema treatments that aim to restore the skin barrier and reduce flare-ups over time.
Primary product
Non-steroidal, pH-correcting OTC eczema creams and kits (pH/LOCK® eczema relief line)
Founded
2021
Headquarters
San Francisco, California, United States
Team size
1-10 employees
Industry
Personal Care Product Manufacturing
Sub-industry
Eczema skincare / medical skincare / D2C personal care
Offices
San Francisco, California, United States
2309 Carquinez Ave, El Cerrito, CA 94530, United States
Business model
Direct-to-consumer ecommerce
Subscription e-commerce
Online retail
Funding
Stage
Seed
Total raised
$500K
Latest round
Seed · Mar 2022
Latest amount
$500K
Mar 2022 · Y Combinator
People & investors
Work & culture
Science-led, mission-driven, and customer-supportive; the company emphasizes in-house medical expertise, personalized guidance, clinical proof, and accessible eczema relief.
Product & market
Pricing
D2C retail with one-time purchases plus subscriptions; public site shows product pricing and subscription discounts (15% off, with some bundle discounts).
Differentiators
- —Patented pH/LOCK® buffering system
- —Non-steroidal, OTC eczema relief
- —Aims to maintain optimal skin pH for up to 12 hours
- —Clinical trial-backed positioning
- —Dermatologist-recommended / medical-advisor-backed
- —Product line for babies, flare-ups, and long-term maintenance
Technology
Shopify
Google Analytics
Cookies / pixels / SDKs
Customers
People with eczema
Babies and toddlers (0-5)
Children and families
Parents and caregivers
Sensitive-skin consumers
Competitors
CeraVe
Eucerin
La Roche-Posay
Goop
TULA
PROVEN
Scale & contact
Estimated revenue
Approximately $1.9M annual revenue (third-party estimate)
Estimated monthly visits
10.7K
Traffic estimate as of Oct 2024
Latest news
SFGATE Story Studio · Nov 2025
Story Studio feature highlighting Soteri Skin's Harvard-developed, pH-correcting eczema treatment and its positioning around long-lasting relief.
Business Standard · Jul 2023
Press coverage of Soteri Skin's exclusive India launch partnership with Clinikally, describing the brand as a pH-correcting, steroid-free eczema solution and noting availability through Clinikally's channels.
ThePrint / ANI · Jul 2023
Republished press release covering the Clinikally partnership, India expansion, and Soteri Skin's steroid-free eczema products.
RetailBoss · May 2023
Another article on the Clinikally partnership and India market expansion for Soteri Skin's eczema-care line.
Jobs and careers at SOTERI SKIN
0 jobs at SOTERI SKIN
No open positions
Check back later for new openings